Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
about
Memantine for dementiaFailures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insultsVascular dementiaVascular risk factors and dementia: how to move forward?N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's diseasePost-stroke cognitive impairment: epidemiology, mechanisms and managementStroke, dementia, and drug deliveryThe chemical biology of clinically tolerated NMDA receptor antagonistsPharmacologically targeted NMDA receptor antagonism by NitroMemantine for cerebrovascular diseaseBinswanger's disease: toward a diagnosis agreement and therapeutic approachWhite matter hyperintensities, cognitive impairment and dementia: an update.Ischemic brain injury in cerebral amyloid angiopathyInteraction study of acetylcholinestrase inhibitors on pharmacokinetics of memantine in rat plasma by HPLC-fluorescence method.A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence.Promotion of the mind through exercise (PROMoTE): a proof-of-concept randomized controlled trial of aerobic exercise training in older adults with vascular cognitive impairmentDrugs for Alzheimer's disease: are they effective?Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association.The science of stroke: mechanisms in search of treatments.Vascular cognitive impairment: Current concepts and Indian perspective.Screening for cognitive decline following single known stroke using the Mini-Mental State Examination.Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia.Vascular cognitive impairment: disease mechanisms and therapeutic implications.Evaluation and management of the elderly patient presenting with cognitive complaints.The dichotomy of memantine treatment for ischemic stroke: dose-dependent protective and detrimental effects.Evaluation of memantine for the treatment of Alzheimer's disease.Memantine: an antiglutamatergic option for dementia.Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology.Agreement between Patient and Proxy Assessments of Quality of Life among Older Adults with Vascular Cognitive Impairment Using the EQ-5D-3L and ICECAP-ODisruption of NMDAR-CRMP-2 signaling protects against focal cerebral ischemic damage in the rat middle cerebral artery occlusion modelMemantine: targeting glutamate excitotoxicity in Alzheimer's disease and other dementias.Models and mechanisms of vascular dementia.Role of the pro-inflammatory cytokines TNF-alpha and IL-1beta in HIV-associated dementia.Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.NMDA receptors in clinical neurology: excitatory times ahead.Memantine in the treatment of mild-to-moderate Alzheimer's disease.Investigational treatment for vascular cognitive impairment.Therapeutic issues in vascular dementia: studies, designs and approaches.Vascular dementia: pharmacological treatment approaches and perspectivesNeuropsychiatric symptoms in patients with vascular dementia in mainland China.Hydrogen Sulfide Prevents Synaptic Plasticity from VD-Induced Damage via Akt/GSK-3β Pathway and Notch Signaling Pathway in Rats.
P2860
Q22252980-52CC07B1-AA2E-417C-8BB9-DB3EBA4BD9C0Q24558984-6DBAB714-13F5-43D6-9044-9D83F1AEA3C6Q24629003-93BA11E1-EE9A-4416-AE6C-CE87CB0D1604Q24650263-BAB32FB2-1CC0-49C0-BAF7-32458D99DBDAQ26825619-5D15ACDE-23FF-46A8-8A09-602B175DAE8DQ26865422-00447EE6-BFAD-4E40-B4E0-9D0ABCB8981CQ28166505-929A5700-407F-4652-A6C8-8E8B9E4A7906Q28248958-D9FE2251-4E21-4A03-BB5C-C478598ABFAAQ29243373-FAD24A64-437B-4563-86B5-8BB9D0D75CE3Q30848732-A31F6F31-6029-4D21-88C3-2930D3E86C70Q30893715-9CF0D0FA-C26A-440D-A723-538DBB08BC6CQ30945201-6C367328-AAB2-40E4-AFD3-368F3C3E22DDQ31123284-8FF026E4-54B9-4502-93D6-5EC36D189D5EQ33165693-3C1D56F3-0A00-464B-A481-06D85AAAAE7FQ33531561-790133C6-31BA-4EE7-AACD-FC08E09E7E03Q33865325-BD5809AB-FF11-4F61-BA3C-047394B1465CQ33967781-4222F077-D362-4178-BF04-C9C1D536B904Q34212337-DE5D5B7E-6A1D-434C-ACBF-6C6D1CA237F8Q34574965-EAFEA8E4-61CF-4726-B340-4183DC71597DQ34956402-B649D72B-2795-4F65-9406-1BD9515E0AF6Q35117821-D74D2692-6C9F-4A87-B62E-E78155C42691Q35197111-B1E30D9A-7771-49CE-A023-456431CC103BQ35447239-D5059646-6428-4AFD-8EB8-196FD84BD623Q35591224-343076DD-E12E-4AFE-8AEB-75DCE562111DQ35594009-778CFA59-487B-4D61-8410-B2296EC5B95EQ35683081-8C627E3A-F37B-4474-BB33-939589E1B9E8Q35770190-53CCCF7F-9AC2-4F4F-B329-0AA9979656EFQ35996331-1DD2241A-CA7E-42C4-A79E-596F8C78AF35Q36009624-E46833BC-5D1D-4487-9785-CC95993CEB21Q36103890-F137784F-3C93-4767-9F88-848EEA5257DFQ36244982-46914778-659F-4109-9BE9-5098B42349FDQ36516922-ECEEECE1-9FD2-48C7-BB30-8CC893C0EA4EQ36632771-D3159DDE-ED52-4309-9D21-B2A631B5CE9AQ36660216-1F9D253A-804D-4069-8483-45879A331EA5Q36719691-E0B9E5B8-7088-44BF-BB7A-81212B632D57Q36802613-9BAD1D4D-9607-49E9-9420-581376F66721Q36808830-52AB25D3-E3F1-44DD-8C45-A710678F4D41Q37017429-F034705E-7CEB-48E1-BAB7-AF35F7B7163DQ37074562-B149F442-420E-4B9E-B1E4-35EA32CCDDBCQ37075664-C93D8F00-86FC-4378-936A-BE6DE45559E3
P2860
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Efficacy and safety of memanti ...... bo-controlled trial (MMM 300).
@en
Efficacy and safety of memanti ...... bo-controlled trial (MMM 300).
@nl
type
label
Efficacy and safety of memanti ...... bo-controlled trial (MMM 300).
@en
Efficacy and safety of memanti ...... bo-controlled trial (MMM 300).
@nl
prefLabel
Efficacy and safety of memanti ...... bo-controlled trial (MMM 300).
@en
Efficacy and safety of memanti ...... bo-controlled trial (MMM 300).
@nl
P2093
P921
P1433
P1476
Efficacy and safety of memanti ...... bo-controlled trial (MMM 300).
@en
P2093
Albrecht Stöffler
Anne-Sophie Rigaud
Françoise Forette
Hans-Jorgen Möbius
Jean-Marc Orgogozo
P304
P356
10.1161/01.STR.0000020094.08790.49
P407
P577
2002-07-01T00:00:00Z